Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?

Journal Article (Journal Article)

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common X-linked mutation that is more prevalent in African, Asian, Latin American and Mediterranean populations. Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia. Given the potential for coronavirus to trigger oxidative stress, unrecognized G6PD deficiency in the presence of the COVID-19 viral infection may cause hemolytic crisis and worse outcome in affected individuals. Further, since certain drugs that may be used to treat COVID-19 infection may cause hemolytic crisis in individuals with G6PD deficiency, it may be warranted to recommend adding G6PD deficiency to the list of screening elements in a COVID-19 workup for those patients where there is a high suspicion for this genetic mutation.

Full Text

Duke Authors

Cited Authors

  • Jamerson, BD; Haryadi, TH; Bohannon, A

Published Date

  • October 2020

Published In

Volume / Issue

  • 51 / 7

Start / End Page

  • 743 - 744

PubMed ID

  • 32600868

Pubmed Central ID

  • PMC7275985

Electronic International Standard Serial Number (EISSN)

  • 1873-5487

Digital Object Identifier (DOI)

  • 10.1016/j.arcmed.2020.06.006


  • eng

Conference Location

  • United States